Im SA - Search Results

1

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF. Paoletti C, et al. Among authors: im sa. Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6. Clin Cancer Res. 2018. PMID: 30082476 Clinical Trial.

2

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Han SW, et al. Among authors: im sa. Clin Cancer Res. 2006 Apr 15;12(8):2538-44. doi: 10.1158/1078-0432.CCR-05-2845. Clin Cancer Res. 2006. PMID: 16638863

3

High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.

Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS. Lee KH, et al. Among authors: im sa. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6. doi: 10.1158/1078-0432.CCR-05-2710. Clin Cancer Res. 2006. PMID: 16857796

4

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Keam B, et al. Among authors: im sa. Breast Cancer Res Treat. 2009 Jul;116(1):153-60. doi: 10.1007/s10549-008-0160-9. Epub 2008 Sep 12. Breast Cancer Res Treat. 2009. PMID: 18787948 Clinical Trial.

5

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. Rhee J, et al. Among authors: im sa. BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307. BMC Cancer. 2008. PMID: 18947390 Free PMC article.

6

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy.

Yhim HY, Han SW, Oh DY, Han W, Im SA, Kim TY, Kim YT, Noh DY, Chie EK, Ha SW, Park IA, Bang YJ. Yhim HY, et al. Among authors: im sa. Cancer. 2010 Jun 15;116(12):2890-901. doi: 10.1002/cncr.25054. Cancer. 2010. PMID: 20564396 Free article.

7

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.

Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ, Kim TY. Chang HJ, et al. Among authors: im sa. Jpn J Clin Oncol. 2011 May;41(5):593-9. doi: 10.1093/jjco/hyr020. Epub 2011 Mar 15. Jpn J Clin Oncol. 2011. PMID: 21406492

8

Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.

Keam B, Im SA, Park S, Nam BH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Keam B, et al. Among authors: im sa. J Cancer Res Clin Oncol. 2011 Sep;137(9):1301-8. doi: 10.1007/s00432-011-0991-3. Epub 2011 Jun 30. J Cancer Res Clin Oncol. 2011. PMID: 21717200

9

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Keam B, et al. Among authors: im sa. BMC Cancer. 2011 Oct 20;11:452. doi: 10.1186/1471-2407-11-452. BMC Cancer. 2011. PMID: 22011459 Free PMC article. Clinical Trial.

10

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Im SA, et al. Among authors: im yh. Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094934 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

703 results

Search Page

Filters